Developing new treatments for nerve pain using AT2 inhibitors
Development of Angiotensin AT2 inhibitors for neuropathic pain relief
This study is exploring a new way to help people with nerve pain feel better by targeting a specific receptor in the body, which could lead to safer pain relief options that don't involve addictive medications like opioids.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Southern California NIH-funded |
| Lab location | 1 site (Los Angeles, UNITED STATES) |
| Project ID | NIH-11139279 on NIH RePORTER |
What this research studies
This research focuses on finding new ways to relieve neuropathic pain, which affects millions of Americans and is often inadequately treated with current medications. The approach involves targeting the angiotensin AT2 receptor, which plays a role in how nerve cells respond to pain. By developing new inhibitors that can effectively block this receptor, the research aims to provide a safer alternative to opioid painkillers, reducing the risk of addiction and side effects. The study will build on previous findings that showed promise in preclinical and early clinical trials.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals experiencing chronic neuropathic pain, such as those with diabetic neuropathy or post-herpetic neuralgia.
Not a fit: Patients who do not have neuropathic pain or those whose pain is not related to the conditions being studied may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer pain relief options for patients suffering from neuropathic pain.
How similar studies have performed: Previous research has shown promise in targeting the angiotensin AT2 receptor for pain relief, although the specific approach being tested in this study is novel.
Where this research is happening
Los Angeles, UNITED STATES
- University of Southern California — Los Angeles, United States (Active)
Researchers
- Principal investigator: Katritch, Vsevolod — University of Southern California
- Study coordinator: Katritch, Vsevolod
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.